Kook Hwan Kim

Kook Hwan Kim

Auto-generated profile, based on publicly available information

Kook Hwan Kim

Research Institute, GI Innovation Inc, Songpa-gu, Korea (the Republic of)

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2012 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
KKKook Hwan Kim
Kook Hwan Kim
YJYeon Taek Jeong
Yeon Taek Jeong
HOHyunhee Oh
Hyunhee Oh
SKSeong Hun Kim
Seong Hun Kim
JCJae Min Cho
Jae Min Cho
MLMyung-Shik Lee
Myung-Shik Lee

1 May 2007 in Gastroenterology
Verified
Journal Article
Closed access
KKKook Hwan Kim
Kook Hwan Kim
HSHye–Jun Shin
Hye–Jun Shin
KKKyeongjin Kim
Kyeongjin Kim
HCHyun Mi Choi
Hyun Mi Choi
SRSang Hoon Rhee
Sang Hoon Rhee
JCJaehun Cheong
Jaehun Cheong

7 May 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KKKook Hwan Kim
Kook Hwan Kim
SKSeong Hun Kim
Seong Hun Kim
YMYoung-Ki Min
Young-Ki Min
HYHun-Mo Yang
Hun-Mo Yang
JLJeong-Beom Lee
Jeong-Beom Lee
MLMyung-Shik Lee
Myung-Shik Lee
Fibroblast growth factor 21 (FGF21) plays an important role in the regulation of energy homeostasis during starvation and has an excellent therapeutic potential for the treatment of type 2 diabetes in rodents and monkeys. Acute exercise affects glucose and lipid metabolism by increasing glucose uptake and lipolysis. However, it is not known whether acute exercise affects FGF21 expression. Here, we showed that serum FGF21 level is increased in mice after a single bout of acute exercise, and that this is accompanied by increased serum levels of free fatty acid, glycerol and ketone body. FGF21 gene expression was induced in the liver but not in skeletal muscle and white adipose tissue of mice after acute exercise, and further, the gene expression levels of hepatic peroxisome proliferator-activated receptor α (PPARα) and activating transcription factor 4 (ATF4) were also increased. In addition, we observed increased FGF21 level in serum of healthy male volunteers performing a treadmill run at 50 or 80% VO 2 max. These results suggest that FGF21 may also be associated with exercise-induced lipolysis in addition to increased catecholamines and reduced insulin.

1 January 2014 in Diabetes & Metabolism Journal
Verified
Journal Article
Open access
PDF file
KKKook Hwan Kim
Kook Hwan Kim
MLMyung-Shik Lee
Myung-Shik Lee
Fibroblast growth factor 21 (FGF21) is an endocrine hormone that is primarily expressed in the liver and exerts beneficial effects on obesity and related metabolic diseases. In addition to its remarkable pharmacologic actions, the physiological roles of FGF21 include the maintenance of energy homeostasis in the body in conditions of metabolic or environmental stress. The expression of FGF21 is induced in multiple organs in response to diverse physiological or pathological stressors, such as starvation, nutrient excess, autophagy deficiency, mitochondrial stress, exercise, and cold exposure. Thus, the FGF21 induction caused by stress plays an important role in adaptive response to these stimuli. Here, we highlight our current understanding of the functional importance of the induction of FGF21 by diverse stressors as a feedback mechanism that prevents excessive stress.

24 December 2014 in Diabetologia
Verified
Journal Article
Closed access
PDF file
SKSeong Hun Kim
Seong Hun Kim
KKKook Hwan Kim
Kook Hwan Kim
HKHyoung-Kyu Kim
Hyoung-Kyu Kim
MKMi-Jeong Kim
Mi-Jeong Kim
SBSung Hoon Back
Sung Hoon Back
MLMyung-Shik Lee
Myung-Shik Lee

1 May 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KKKook Hwan Kim
Kook Hwan Kim
SKSeong Hun Kim
Seong Hun Kim
DHDai Hoon Han
Dai Hoon Han
YJYoung Suk Jo
Young Suk Jo
YLYong-ho Lee
Yong-ho Lee
MLMyung-Shik Lee
Myung-Shik Lee
Growth differentiation factor 15 (GDF15) is an endocrine hormone belonging to the TGFβ superfamily member. GDF15 administration or GDF15 overexpression has been reported to have anti-obesity and anti-diabetic effects. Although non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) is frequently associated with obesity and insulin resistance, the functional role of endogenous GDF15 and therapeutic effect of GDF15 overexpression in NASH and related metabolic deterioration have not been evaluated. Here, we found that GDF15 expression was increased in the livers of NASH animal models and human subjects with NASH. Elevated expression of GDF15 was due to diet-induced hepatic endoplasmic reticulum (ER) stress. Gdf15-knockout mice exhibited aggravated NASH phenotypes such as increased steatosis, hepatic inflammation, fibrosis, liver injury, and metabolic deterioration. Furthermore, GDF15 directly suppressed expression of fibrosis-related genes and osteopontin (OPN), contributing factors for NASH-related fibrosis, in hepatic stellate cells in vitro and in the liver of mice in vivo. Finally, we found that GDF15-transgenic mice showed attenuation of NASH phenotypes and metabolic deterioration. Therefore, our results suggest that induction of endogenous GDF15 is a compensatory mechanism to protect against the progression of NASH and that GDF15 could be an attractive therapeutic candidate for treatment of NASH and NASH-related metabolic deterioration.